Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?
Clinical Lung Cancer · 2023
DOI: 10.1016/j.cllc.2023.03.014 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Lung Cancer, 2023. Verfasst von Noy Meshulami und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Health System, New York, NY; Icahn School of Medicine at Mount Sinai, New York, NY. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
Lung cancer is responsible for 1.8 million annual deaths. Non-small cell lung cancers (NSCLC) represent 85% of lung cancer tumors. While surgery is an effective early-stage treatment, the majority of newly identified US lung cancer cases are stage III/IV. Immunotherapy, using programmed death-ligand 1 (PD-L1) or programmed death 1 (PD-1) receptor antibody therapeutics, has increased survival for patients with NSCLC. PD-L1 protein expression is widely used as a predictive biomarker informing treatment decisions. However, only a minority of patients (27%-39%) respond to PD-L1/PD-1 treatment. PD-L1 protein expression by immunohistochemistry assay has deficiencies in identifying responding and refractory patients. Given the different characteristics of squamous and nonsquamous NSCLC, the predictability of PD-L1 levels in determining which patients would benefit from immunotherapy could vary between the 2 histologies. We analyzed 17 phase-III clinical studies and a retrospective study to determine if the predictive capability of PD-L1 expression varies between squamous and nonsquamous NSCLC. For patients with NSCLC treated with mono or dual-immune checkpoint inhibitors (ICI), PD-L1 expression was more predictive of benefit for patients with nonsquamous NSCLC than squamous NSCLC. Patients with nonsquamous histology and PD-L1 high tumor proportion scores (TPS) survived 2.0x longer compared to those with low TPS, when treated with monotherapy ICI. Among patients with squamous NSCLC, that difference was 1.2 to 1.3x. For patients treated with ICIs and chemotherapy, there was no clear difference in the predictive value of PD-L1 levels between histologies. We encourage future researchers to analyze the predictability of PD-L1 biomarker expression separately for squamous and nonsquamous NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Health System, New York, NY; Icahn School of Medicine at Mount Sinai, New York, NY.
- Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Health System, New York, NY.
- Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Health System, New York, NY. Electronic address: fred.hirsch@mssm.edu.
Zitieren
APA
Meshulami, N., Tavolacci, S., de Miguel-Perez, D., Rolfo, C., Mack, P. C., & Hirsch, F. R. (2023). Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2023.03.014
Vancouver
Meshulami N, Tavolacci S, de Miguel-Perez D, Rolfo C, Mack PC, Hirsch FR. Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?. Clinical Lung Cancer. 2023. doi:10.1016/j.cllc.2023.03.014
BibTeX
@article{Meshulami2023,
author = {Meshulami, Noy and Tavolacci, Sooyun and de Miguel-Perez, Diego and Rolfo, Christian and Mack, Philip C and Hirsch, Fred R},
title = {Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?},
journal = {Clinical Lung Cancer},
year = {2023},
doi = {10.1016/j.cllc.2023.03.014}
}
EUVIMED